Summary:
In patients with chronic diabetic foot ulcers, topical application of Wharton’s jelly-derived mesenchymal stem cell (WJ-MSC) exosomes significantly accelerated complete wound healing compared to standard of care alone or standard of care with placebo (CMC vehicle), though it was associated with no significant adverse events, indicating a favorable safety profile.
| PICO | Description |
|---|---|
| Population | Adults (n=110) diagnosed with chronic non-healing diabetic foot ulcers. |
| Intervention | Weekly topical application of Wharton’s jelly-derived mesenchymal stem cell exosomes (WJ-MSC Exos) combined with standard wound care for 4 weeks. |
| Comparison | Standard of care alone (Control group) and standard of care plus carboxymethyl cellulose (CMC) placebo (Placebo group). |
| Outcome | 62% of participants in the treatment group achieved full wound healing, with a mean healing time of 6 weeks (range: 4–8 weeks), significantly faster than the 20 weeks (range: 12–28 weeks) observed in control groups. Minimal adverse events were reported, supporting the treatment’s safety and efficacy. |
Source: Kishta, Mohamed S., et al. “The transforming role of Wharton’s jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial.” Read article here.
